A randomized, double-blind, placebo-controlled, parallel-group, dose response study to evaluate the efficacy and safety of 3 fixed doses (25 mg eq., 100 mg eq., and 150 mg eq.) of paliperidone palmitate in subjects with schizophrenia.

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, dose response study to evaluate the efficacy and safety of 3 fixed doses (25 mg eq., 100 mg eq., and 150 mg eq.) of paliperidone palmitate in subjects with schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 06 Jun 2010 Results have been presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
    • 06 Jun 2010 Results presented at 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
    • 01 Jun 2010 Results have been published in the Journal of Clinical Psychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top